Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348695 | 1.00 | MEN1 (0.40) | MEN1KMT2APTPN1CREBBPEP300 | |
| SCHEMBL2301912 | 0.84 | MEN1 (0.34) | MEN1KMT2APTPN1CREBBPMGLL | |
| SCHEMBL2301907 | 0.84 | MEN1 (0.34) | MEN1KMT2APTPN1CREBBPMGLL | |
| SCHEMBL2141379 | 0.83 | MEN1 (0.49) | MEN1KMT2A | |
| SCHEMBL2141382 | 0.83 | MEN1 (0.49) | MEN1KMT2A | |
| SCHEMBL11066833 | 0.79 | USP2 (0.40) | MEN1KMT2A | |
| SCHEMBL11066878 | 0.79 | USP2 (0.40) | MEN1KMT2A | |
| SCHEMBL939342 | 0.79 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL20118725 | 0.77 | MEN1 (0.44) | MEN1KMT2ACREBBPEP300 | |
| SCHEMBL1114731 | 0.77 | MEN1 (0.44) | MEN1KMT2ACREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338141-A1 | HIV INTEGRASE INHIBITORS | ISAACS RICHARD C (US) | 2013-12-19 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2010042391-A2 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042392-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338141-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | MEN1 3763/4885KMT2A 1215/4885PTPN1 3700/4885 |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | MEN1 3763/4885KMT2A 1215/4885PTPN1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.